MDTMedtronic
Is it safe?
Strong, no red flags: a safe balance sheet, clean books, and quality strong.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
High fundamental quality Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Insiders were net sellers (-$139K, 90 days to Oct 8, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Relatively steady, low volatility. Worst drawdown -45% · now 15% below its 52-week high.
Unless marked, from SEC EDGAR, as of Apr 24, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can MDT take a bad year?
Medtronic carries $19.3B of net debt at 2.19× EBITDA: a load its earnings can carry.
Net debt · as at Q1 2027 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 2.19×
Net debt / EBITDA · 2.49× a year ago · the load is coming down
- Altman Z-score
- 2.70
Altman Z-score · grey zone, between 1.8 and 3
- Interest cover
- 9.37×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ1 2027
- $28.2B
- Cash and short-term investments
- $8.82B
- Net debt
- $19.3B
- EBITDA, trailing twelve months
- $8.82B
- Operating profit, trailing twelve months
- $6.79B
- Debt / equity
- 0.56×
- Total debt / EBITDA
- 3.19×
- Annualised volatilitytwo years of daily moves
- 22%
- Worst drawdown on file
- −45%
- Below its 52-week high
- 15%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Medical Devices
The closest names by size in the same industry